| pubmed-article:8781065 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8781065 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:8781065 | lifeskim:mentions | umls-concept:C0001563 | lld:lifeskim |
| pubmed-article:8781065 | lifeskim:mentions | umls-concept:C0600688 | lld:lifeskim |
| pubmed-article:8781065 | lifeskim:mentions | umls-concept:C0678723 | lld:lifeskim |
| pubmed-article:8781065 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:8781065 | lifeskim:mentions | umls-concept:C0037791 | lld:lifeskim |
| pubmed-article:8781065 | lifeskim:mentions | umls-concept:C0066733 | lld:lifeskim |
| pubmed-article:8781065 | lifeskim:mentions | umls-concept:C0458003 | lld:lifeskim |
| pubmed-article:8781065 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:8781065 | pubmed:dateCreated | 1997-3-7 | lld:pubmed |
| pubmed-article:8781065 | pubmed:abstractText | The objective of this study was to further characterize the developmental toxicity of mono-n-butyl phthalate (MBuP), which is one of the major metabolites of n-butyl benzyl phthalate (BBP) and di-n-butyl phthalate (DBP). Pregnant rats were given MBuP by gastric intubation at a dose of 500, 625 or 750 mg/kg on days 7-9, days 10-12, or days 13-15 of pregnancy. A significantly increased incidence of postimplantation loss was noted in pregnant rats given MBuP on days 7-9 and days 10-12 at doses of 625 mg/kg and above and on days 13-15 at doses of 500 mg/kg and above. No evidence of teratogenicity was found when MBuP was given on days 10-12 of pregnancy. A significantly increased incidence of fetuses with external malformations was found after treatment with MBuP on days 7-9 and days 13-15 at doses of 625 and 750 mg/kg. A significantly increased incidence of fetuses with skeletal malformations was observed after treatment with MBuP on days 7-9 at doses of 500 mg/kg and above and on days 13-15 at doses of 625 mg/kg and above. Deformity of the cervical vertebrae was predominantly observed following treatment with MBuP on days 7-9. Cleft palate and fusion of the sternebrae were exclusively found following treatment with MBuP on days 13-15. It could be concluded that the manifestation of deviant development induced by MBuP varies with the developmental stage at the time of administration. | lld:pubmed |
| pubmed-article:8781065 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8781065 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8781065 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8781065 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8781065 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8781065 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8781065 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:8781065 | pubmed:issn | 0090-4341 | lld:pubmed |
| pubmed-article:8781065 | pubmed:author | pubmed-author:OgawaYY | lld:pubmed |
| pubmed-article:8781065 | pubmed:author | pubmed-author:FOGJJ | lld:pubmed |
| pubmed-article:8781065 | pubmed:author | pubmed-author:AmanoHH | lld:pubmed |
| pubmed-article:8781065 | pubmed:author | pubmed-author:KurosakaRR | lld:pubmed |
| pubmed-article:8781065 | pubmed:author | pubmed-author:HarazonoAA | lld:pubmed |
| pubmed-article:8781065 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8781065 | pubmed:volume | 31 | lld:pubmed |
| pubmed-article:8781065 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8781065 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8781065 | pubmed:pagination | 170-6 | lld:pubmed |
| pubmed-article:8781065 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8781065 | pubmed:meshHeading | pubmed-meshheading:8781065-... | lld:pubmed |
| pubmed-article:8781065 | pubmed:meshHeading | pubmed-meshheading:8781065-... | lld:pubmed |
| pubmed-article:8781065 | pubmed:meshHeading | pubmed-meshheading:8781065-... | lld:pubmed |
| pubmed-article:8781065 | pubmed:meshHeading | pubmed-meshheading:8781065-... | lld:pubmed |
| pubmed-article:8781065 | pubmed:meshHeading | pubmed-meshheading:8781065-... | lld:pubmed |
| pubmed-article:8781065 | pubmed:meshHeading | pubmed-meshheading:8781065-... | lld:pubmed |
| pubmed-article:8781065 | pubmed:meshHeading | pubmed-meshheading:8781065-... | lld:pubmed |
| pubmed-article:8781065 | pubmed:meshHeading | pubmed-meshheading:8781065-... | lld:pubmed |
| pubmed-article:8781065 | pubmed:meshHeading | pubmed-meshheading:8781065-... | lld:pubmed |
| pubmed-article:8781065 | pubmed:meshHeading | pubmed-meshheading:8781065-... | lld:pubmed |
| pubmed-article:8781065 | pubmed:meshHeading | pubmed-meshheading:8781065-... | lld:pubmed |
| pubmed-article:8781065 | pubmed:meshHeading | pubmed-meshheading:8781065-... | lld:pubmed |
| pubmed-article:8781065 | pubmed:meshHeading | pubmed-meshheading:8781065-... | lld:pubmed |
| pubmed-article:8781065 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8781065 | pubmed:articleTitle | Phase specificity of developmental toxicity after oral administration of mono-n-butyl phthalate in rats. | lld:pubmed |
| pubmed-article:8781065 | pubmed:affiliation | National Institute of Health Sciences, Osaka Branch, 1-1-43, Hoenzaka, Chuo-ku, Osaka 540, Japan. | lld:pubmed |
| pubmed-article:8781065 | pubmed:publicationType | Journal Article | lld:pubmed |
